Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Hospitalized Acute Gout
NCT00663169Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Primary completion
- Oct 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of canakinumab in acute gouty arthritis, sponsored by Novartis. Started Apr 2008; status: completed.
02
Drugs
canakinumab
03
Conditions
acute gouty arthritis
Beyond the preview
Go deeper on NCT00663169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663169.